• Important Safety Information | 
  • Full Prescribing Information | 
  • Contact Us | 
  • Log Out
  • Menu
  • Home

Macrilen Co-Pay Savings Program

Please register in order to enroll your patients in the Macrilen Co-Pay Savings Program and file claims electronically.

For prescribers who are purchasing Macrilen through an authorized distributor, sign-up for the Macrilen Co-Pay Savings portal to enroll your patients and submit claims.

Eligible commercially-insured patients may pay as little as $0 for Macrilen (with an annual cap of $1,000).

Please Login:

*Required field

If you have forgotten your Username or Password, please call the help desk at 1-844-622-2443 (8:00 AM to 8:00 PM ET, Monday through Friday, except holidays).

Need to register?

If you are not currently registered with a username and password, please contact the Macrilen Co-Pay Savings Program Help Desk at 1-844-622-2443 (8:00 AM to 8:00 PM ET, Monday through Friday, except holidays) for assistance with the setup of your log-in information.

Terms and Conditions:

  1. The Macrilen Co-Pay Savings Program (“Program”) can be used by patients who are U.S. citizens or residents. Patients must be 18 years or older to use the Program.
  2. The Program is limited to one per person and is not transferable. No substitutions are permitted. This Program is available for each valid prescription. No other purchase is necessary. The offer cannot be combined with any other coupon, free trial, discount, prescription savings card, or other offer. Patient may not be currently receiving free drug assistance through Strongbridge patient assistance programs.
  3. The Program is not insurance and is not intended to substitute for insurance.
  4. The Program is valid only for patients with commercial insurance and is not valid for prescriptions that are eligible to be reimbursed:
    • In whole or part, by Medicare, Medicaid or a Medicare Part D Plan, Tricare, VA, DOD, Puerto Rico Government Health Insurance Plan, or any other federal or state-funded healthcare benefit program (collectively, "government programs")
    • Or by commercial plans or other health or pharmacy benefit programs that reimburse for the entire cost of prescription drugs.
  5. Patients without insurance coverage are considered “cash-pay” patients and are not eligible. Medicare Part D enrollees who are in the prescription drug coverage gap (the “donut hole”) are not eligible for the co-pay coupon. Patients who begin receiving prescription benefits from such Government Programs at any time will no longer be eligible to use the Program.
  6. Void where prohibited by law, taxed, or restricted. The Program shall follow state restrictions in relation to AB-rated generic equivalents where applicable (e.g. MA, CA).
  7. Patient, pharmacist, and prescriber agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer. Both patient and pharmacist are each individually responsible for reporting receipt of savings benefit to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Program, as required.
  8. It is illegal to sell, purchase, trade, or counterfeit, or offer to sell, purchase, trade, or counterfeit the Program.
  9. Strongbridge reserves the right to terminate, rescind, revoke, or modify this Program at any time without notice.
Important Safety Information for Macrilen
Indication

Macrilen is indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Limitations of Use

The safety and diagnostic performance of Macrilen have not been established for subjects with a body mass index (BMI) > 40 kg/m2.

Warnings and Precautions

QT Prolongation

Macrilen causes an increase of about 11 msec in the corrected QT (QTc) interval. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of Macrilen with drugs that are known to prolong the QT interval should be avoided.

Potential for False Positive Test Results with Use of Strong CYP3A4 Inducers

Concomitant use of strong CYP3A4 inducers with Macrilen can decrease macimorelin plasma levels significantly and thereby lead to a false positive result. Strong CYP3A4 inducers should be discontinued and enough time should be given to allow washout of CYP3A4 inducers prior to test administration.

Potential for False Negative Test Results in Recent Onset Hypothalamic Disease

Adult growth hormone (GH) deficiency caused by a hypothalamic lesion may not be detected early in the disease process. Macimorelin acts downstream from the hypothalamus and macimorelin stimulated release of stored GH reserves from the anterior pituitary could produce a false negative result early when the lesion involves the hypothalamus. Repeat testing may be warranted in this situation.

Adverse Reactions

The most common adverse reactions were dysgeusia, dizziness, headache, fatigue, nausea, hunger, diarrhea, upper respiratory tract infection, feeling hot, hyperhidrosis, nasopharyngitis, and sinus bradycardia.

Please see Full Prescribing Information.

© 2018 Strongbridge Biopharma plc

STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.

Macrilen™ is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.

Macrilen is the subject of U.S. Patent Nos 6,861,409 and 8,192,719.

MAC-0177          08/2018



900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: 1-844-622-2443
macrilen_info@strongbridgebio.com


Privacy Statement
Compliance Program
California Statement of Compliance
Strongbridge Biopharma